HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

candesartan cilexetil (Amias)

Subscribe to New Research on candesartan cilexetil

a prodrug which is metabolized to an active form (CV-11974) to exert its biological effects; angiotensin receptor antagonist

Also Known As:

Amias; Atacand; Kenzen; 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate; Almirall brand of candesartan cilexetil; Astra brand of candesartan cilexetil; AstraZeneca brand of candesartan cilexetil; Blopress; Parapres; Promed brand of candesartan cilexetil; TCV 116; TCV-116; Takeda brand of candesartan cilexetil; 1H-Benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)-

Networked: 272 relevant articles (48 outcomes, 77 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results

Experts

1.	Asmar, R: 5 articles (01/2009 - 11/2000)
2.	Michelson, E L: 5 articles (07/2001 - 04/2000)
3.	Trenkwalder, P: 4 articles (01/2005 - 01/2000)
4.	Matsuoka, H: 4 articles (10/2001 - 01/2001)
5.	Kobayashi, N: 4 articles (10/2001 - 01/2001)
6.	Sugaya, Takeshi: 3 articles (10/2005 - 03/2002)
7.	Salvetti, Massimo: 3 articles (04/2005 - 11/2002)
8.	Tsubokou, Y: 3 articles (10/2001 - 01/2001)
9.	Ushiyama, C: 3 articles (11/2000 - 09/2000)
10.	Shimada, N: 3 articles (11/2000 - 09/2000)

Related Diseases

1.	Hypertension (High Blood Pressure) 06/01/2001 - "Thus, candesartan cilexetil either alone or as add-on therapy was highly effective for the control of systolic or diastolic hypertension regardless of demographic background when used in typical clinical practice settings." 10/15/1998 - "In conclusion, candesartan cilexetil administered once daily effectively reduces BP in a dose-related manner while maintaining safety and tolerability; doses of 16 and 32 mg are most effective for treatment of hypertension." 01/01/2001 - "Thus, the new fixed-dose AT1-receptor blocker/diuretic combination, candesartan cilexetil-HCT 16/12.5 mg combines enhanced efficacy with excellent tolerability and sets a new standard for the treatment of hypertension requiring more than monotherapy." 01/01/2002 - "The efficacy of candesartan cilexetil is not affected by age, and the drug provided significant BP reductions in Black patients and in those with severe hypertension. " 01/01/2004 - "Candesartan cilexetil can be considered an effective and safe alternative to other common antihypertensive monotherapies in a large spectrum of patients with mild and moderate hypertension." Order ALL the reference details at left...
2.	Heart Failure 01/01/2004 - "ARCH-J study showed that candesartan cilexetil, 8 mg/day, significantly improved the progression of heart failure when compared with placebo." 01/01/2000 - "Initial clinical studies have indicated that candesartan cilexetil is well tolerated and effective in patients with heart failure. " 01/01/2000 - "Administration of candesartan cilexetil reduces cardiac preload and afterload and is expected to be useful for the treatment of congestive heart failure." 10/01/2003 - "AIMS: This 6-month study examined the safety and efficacy of candesartan cilexetil, 8 mg once daily, to prevent the progression of congestive heart failure (CHF). " 01/01/2005 - "Candesartan cilexetil: a review of its use in the management of chronic heart failure." Order ALL the reference details at left...
3.	Stroke (Strokes) 01/01/2006 - "The use of candesartan cilexetil as part of antihypertensive therapy in elderly patients with elevated blood pressure was also deemed to be cost effective in a Swedish analysis, primarily resulting from a reduced risk of nonfatal stroke (as shown in the SCOPE study); however, the generalisability of results to other contexts has not been established. " 07/01/2003 - "BACKGROUND AND PURPOSE: The Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) study was designed to assess the safety of modest blood pressure reduction by candesartan cilexetil in the early treatment of stroke. " 07/01/2003 - "The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors." 04/01/2004 - "Acute candesartan cilexetil therapy in stroke survivors." 12/01/2003 - "Re: Evaluation of acute candesartan cilexetil therapy in stroke survivors." Order ALL the reference details at left...
4.	Fibrosis (Cirrhosis) 02/01/2009 - "Surprisingly, the degree of cardiac fibrosis in candesartan cilexetil-treated SDT rats was less than that of SD rats. " 09/01/2003 - "RESULTS: Candesartan cilexetil treatment significantly reduced the fibrosis development. " 05/01/2000 - "Experiments were conducted to determine the effects of ET(A) receptor antagonism (A-127722) and AT(1) receptor antagonism (candesartan cilexetil) on the development of renal fibrosis and the decline of renal function. " 01/01/1994 - "We investigated the preventive effect of an AII receptor antagonist, TCV-116, on the development of cardiac hypertrophy and fibrosis in spontaneously hypertensive rats (SHR) at 24 weeks of age through histopathological study and an AII receptor assay. " 12/01/1997 - "MATERIALS AND METHODS: Stroke-prone spontaneously hypertensive rats were given candesartan cilexetil, a specific non-peptide AT1-receptor antagonist, for 10 weeks, and cardiac phenotypic and fibrosis-related gene expression and aortic and mesenteric arterial gene expressions were determined. " Order ALL the reference details at left...
5.	Cardiomegaly (Heart Hypertrophy) 10/01/1997 - "Another AT1 receptor antagonist, candesartan cilexetil (1 or 3 mg/kg/day for 2 weeks), also prevented this type of cardiac hypertrophy. " 04/01/1996 - "AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats." 12/01/1995 - "TCV-116 also suppressed cardiac hypertrophy. " 01/01/1994 - "We conclude that TCV-116 can prevent neointimal formation after balloon injury as well as reducing blood pressure and preventing cardiac hypertrophy." 10/01/1997 - "Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Hydrochlorothiazide (Esidrix)
2.	Enalapril
3.	Collagen Type I (Type I Collagen)
4.	Losartan (Cozaar)
5.	Angiotensin II
6.	Messenger RNA (mRNA)
7.	candesartan
8.	Type 1 Angiotensin Receptor
9.	Amlodipine (Norvasc)
10.	candesartan cilexetil (Amias)

Related Therapies and Procedures

1.	Homologous Transplantation (Allograft)
2.	Surgical Instruments (Clip)
3.	Transplants (Transplant)
4.	Stents
5.	Renal Dialysis (Hemodialysis)

blog comments powered by Disqus

TREATMENT OPTIONS
for Hypertension,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 3903 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>